Cadrenal Therapeutics, Inc.
CVKD
Last
$0.91
Day
-2.1%
1y
-93.4%
5y
-98.5%
52w
-93.6%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0929d
EMA 21
1.10
EMA 50
1.50
EMA 200
4.49
20d high
-31.4%
5y high
-99.1%
5y range
0th
Positions held
Your positionsCVKD isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-9
Hold
avoid
Signal
Sell
Target
$1.15
Stop
$0.74
Stop distance
18.7%
Target vs last
+26.4%
Fundamentals
| Market cap | $3.32M | Enterprise value | $928,298 | Trailing P/E | — | Forward P/E | -0.27 |
| PEG | — | Price / book | 0.70 | Beta | 1.95 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.8% | ROA | -125.9% | Debt / equity | — |
| Current ratio | 3.73 | Free cash flow | -$8.54M | Analyst recommendation | none | Mean target | $14.00 |
| 52w high | $14.50 | 52w low | $0.85 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$3.3M | -$2.5M | -$3.0M | -$2.7M | -$3.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.3M | -$2.5M | -$3.1M | -$2.7M | -$3.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — |
| Net income | -$13.2M | -$10.7M | -$8.4M |
| Gross margin | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$13.5M | -$11.0M | -$7.6M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-21 · Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
2026-09-03 · Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
2026-08-31 · CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
2026-08-03 · CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
Price (daily)
Full chart · RSI · MACD · patternsCVKD · daily-17.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin